Your Article Summary
See Latest ArticlesImmunoGen, Inc. Prices Public Offering of Common Stock
ImmunoGen, Inc., 06/19/09
ImmunoGen, Inc. , a biopharmaceutical company that develops targeted anticancer therapeutics, announced that it has priced a public offering of 5,000,000 shares of its common stock at a price of $7.00 per share. Net proceeds, after underwriting discounts and commissions and expenses, will be approximately $33 million. ImmunoGen has granted the underwriters a thirty day option to purchase up to an additional 750,000 shares to cover over-allotments, if any.
Today in Research & Development...keeping you current
Receive free subspecialty "5-minute updates" via email
GlaxoSmithKline and NanoBio announce OTC licensing agreement for cold sore treatment
GlaxoSmithKline, 12/18/09
ARIAD Announces Full Enrollment in Phase 3 Succeed Trial Evaluating Ridaforolimus in Patients with Metastatic Sarcomas
ARIAD Pharmaceuticals, 12/18/09
CCHIT Appoints Officers
HealthDataManagement, 12/18/09